Animal Stem Cell Therapy Market Segmented By Hemopoietic, Mesenchymal Stem Cells Type by Allogeneic, Autologous Animal Stem Cell Therapy Source for Canine, Feline, Equine Spices
Industry: Healthcare
Published Date: June-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 410
Report ID: PMRREP14941
The global animal stem cell therapy market was valued at US$ 249.9 Mn at the end of 2021, with a projected CAGR of 5.2% for the next ten years, which indicates positive market growth.
Detailed industry analysis reveals that worldwide revenue from animal stem cell therapy is expected to surge to a market valuation of around US$ 437.3 Mn by the end of 2032.
According to Persistence Market Research, mesenchymal stem cell therapy accounted for a market valuation of around US$ 177.7 Mn at the end of 2021, which is around three-fourths of the overall market share. Hemopoietic stem cells accounted for 28.9% share in the global market, as of 2021-end.
| Attribute | Key Insights |
|---|---|
|
Animal Stem Cell Therapy Market Size (2021) |
US$ 249.9 Mn |
|
Projected Market Value (2032) |
US$ 437.3 Mn |
|
Global Market Growth Rate (2022-2032) |
5.2% CAGR |
|
Share of Top 5 Companies |
55.6% |
The global market for animal stem cell therapy expanded at a CAGR rate of 4.7% over the historically analyzed years (2012-2021).
Expansion of the animal stem cell therapy market is directly linked to the rising prevalence of diseases in the growing population of animals. The approval of stem cell-based products is governed by several standard organizations, including the Food and Drug Administration (FDA), the Australian Pesticides and Veterinary Medicines Authority, the European Medicines Agency's (EMA) Committee for Veterinary Medicinal Products (CVMP), and others because these products have a substantial impact on animal health.
Increased spending on veterinary care also helps the animal stem cell therapy market grow. When pet owners hear how safe and beneficial these treatments are for their animals, they get inquisitive and strive to learn everything they can about animal stem cell therapies.
Because allogeneic stem cell therapy is safer and more effective for animals than autologous stem cell therapy, it is hifavoredoured across regions.
The global animal stem cell therapy market is predicted to expand at a CAGR value of 5.2% and record sales of US$ 437.3 Mn by the end of 2032.
“Pet Owners Well-informed and Expect Higher Level of Veterinary Care”
Many attractive prospects for manufacturers of animal stem cell therapy products in developed countries are expected over the forecasted period. Key players have numerous opportunities to expand their businesses in emerging markets as well.
Veterinary treatments are fostered by a range of indicators, including the growing trend of pet humanization and an increase in the number of pet adoptions.
As a result, pet owners will drive positive demand for higher levels of veterinary care, which will increase market prospects. Moreover, a variety of research and development activities will provide manufacturers with attractive opportunities to expand their business in this domain.
“High Costs Associated with Animal Stem Cell Therapy Procedures”
Because the cost of animal stem cell therapy is somewhat high, owners are hesitant to spend a substantial sum of money on their pet's treatment. Also, several standard veterinary hospitals lack the resources to provide stem cell therapy to animals.
Although pet insurance companies cover the cost of stem cell therapy, they do not cover the costs of follow-up operations such as retreatment. There are a large number of pet owners who do not have a pet insurance plan as well, which will have a negative impact on the future growth prospects of the animal stem cell therapy industry.
Why are Animal Stem Cell Therapy Providers Targeting the U.S. Market?
“Greater Penetration of Pet Care Market in the U.S.”
North America held a value market share of 28.5% in the global animal stem cell therapy market in 2021, of which, the U.S. accounted for a market share of 86.3%.
Increased pet adoption rates as a result of the widespread practice of adopting a pet in Western countries have enabled the U.S to become such a high-revenue-generating country. This has boosted the demand for high-quality care for animals such as dogs, cats, and horses.
How is Demand for Animal Stem Cell Therapy Shaping Up in Germany?
“Presence of Key Market Players in Germany”
Germany accounted for 26.5% share of the European animal stem cell therapy market in terms of value at the end of 2021.
This high market share percentage is attributed to the presence of numerous key participants in the market in Germany, such as Boehringer Ingelheim (Global Stem Cell Technology), Aratana Therapeutics, Inc (Elanco), and others, which boosts product availability.
Why is Australia Emerging as a Prominent Market for Animal Stem Cell Therapy?
“Higher Prevalence of Animal Degenerative Joint Diseases”
At the end of 2021, the Australia animal stem cell therapy market was valued at US$ 18.8 Mn and held a market share of 82.1% in Oceania.
The prevalence of osteoarthritis in dogs over the age of one is thought to be as high as 20% in Australia. The most prevalent joint condition identified in veterinary medicine is osteoarthritis, which poses significant obstacles to canine wellbeing.
Animal stem cell therapies for degenerative joint diseases have shown to have a beneficial impact on international market sales growth.
What is the Outlook for India Regarding Animal Stem Cell Therapy?
“Growing Investments in Animal Welfare”
In 2021, India accounted for around 37.9% of the overall value of the South Asian animal stem cell therapy market and is predicted to reach US$ 8.2 Mn in 2022, at a CAGR of 6.4% during the forecast period.
Growing attention toward animal welfare and increased spending on animal healthcare in the country should provide opportunities for industry players in the animal stem cell therapy market for the expansion of service, and comprehensive product portfolio offering.
Which Animal Stem Cell Product is Driving High Market Growth?
“Available Therapies for Chronic Veterinary Arthritis”
Mesenchymal stem cells, among the two product types, accounted for the highest market share of 71.1% by revenue in 2021.
Adult stem cell therapy, in the form of mesenchymal stem (or stromal) cells (MSCs), has recently presented a new paradigm for treating chronic arthritic dogs, ranging from symptom control to bone and cartilage repair, resulting in significant quality-of-life improvements.
MSCs are recognized as a valuable new source of bioactive chemicals with a variety of therapeutic capabilities.
Which Source is Most Preferred for Animal Stem Cell Therapy?
“Allogeneic Stem Cell Therapy Continues to Remain Popular Choice”
The allogeneic source is mostly preferred for stem cell therapy. The allogeneic segment, by source, is driving demand in this market and accounted for around 66.9% of the global market share value at the end of 2021.
Use of invasive stem cell harvesting procedures is negligible in case of the allogeneic stem cell therapy because the stem cells are collected from a healthy donor. Since it is comparatively easy and safe, it holds a high market share.
For Which Indication is Animal Stem Cell Therapy Most Used?
“High Occurrence of Osteoarthritis Driving Demand”
Osteoarthritis accounted for the largest market share of 43.6%, by value, in the year 2021. This is due to the fact that a significant number of felines and canines suffer from osteoarthritis. Many veterinary medical cases have a higher prevalence of common joint ailments, as well as age-related veterinary disorders.
Although market players may aim to provide physical therapy services, the global market is expected to gain traction in terms of growth during the forecasted years as stromal cells used in animal stem cell therapy are able to secrete an array of bioactive factors that direct them to the injury site and aid in pain reduction and inflammation, thereby contributing directly to tissue repair.
The osteoarthritis segment is expected to expand at a CAGR of 4.7% over the forecast period (2022 to 2032).
The market for animal stem cell therapy is moderately fragmented with the presence of well-established players. The market is subject to high competition, and market players actively seek collaborative approaches for new product development to ensure increased product outreach.
Acquisitions and mergers within the industry further promote the market presence of manufacturers, thus propelling the overall industry.
| Attribute | Details |
|---|---|
|
Forecast Period |
2022-2032 |
|
Historical Data Available for |
2012-2021 |
|
Market Analysis |
US$ Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
By Product Type:
By Source:
By Application:
By Species:
By End User:
By Region:
To know more about delivery timeline for this report Contact Sales
The global animal stem cell therapy market was valued at US$ 249.9 Mn in 2021 and is expected to grow 1.7X by 2032.
The animal stem cell therapy industry is set to witness 5.2% CAGR and be valued at US$ 437.3 Mn by 2032.
The market expanded at a CAGR rate of 4.7% between 2012 and 2021.
Boehringer Ingelheim (Global stem cell technology), Aratana Therapeutics, Inc (Elanco), Vetbiologics (U.S. Stem Cell, Inc.), MediVet Biologics LLC (Ardent Animal Health) and VetStem, Inc. are key suppliers of animal stem cell therapy products.
Mesenchymal stem cells accounted for around 71.1% market share in 2021.
The U.S., Germany, U.K., Australia, and Japan account for most demand for animal stem cell therapy.
The U.S. accounts for 86.3% share of the North America market.
The Europe market for animal stem cell therapy is expected to record a CAGR of 5.4% through 2032.
The U.S. and Germany are major manufacturers of animal stem cells.
Japan held a share of around 48.2% in the East Asia animal stem cell therapy market, whereas India accounted for 37.9% of the South Asian market share in 2021.
